This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy of a Bilberry-based Probiotic Product on Glucose Tolerance and Insulin Resistance

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Åsa Håkansson, Lund University
Sponsor:
Information provided by (Responsible Party):
Åsa Håkansson, Lund University
ClinicalTrials.gov Identifier:
NCT03185676
First received: June 12, 2017
Last updated: NA
Last verified: June 2017
History: No changes posted
  Purpose
The impact of a bilberry-based probiotic drink on the postprandial levels of serum glucose and insulin have already been study in the past. The aim of the current study is to evaluate the long term effect of the probiotic bilberry drink on glucose tolerance and insulin resistance in healthy adults and in comparison to a control drink.

Condition Intervention
Insulin Resistance Other: Bilberry Other: beverage without bilberries or probiotics

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Long Term Efficacy of a Bilberry-based Probiotic Product on Glucose Tolerance and Insulin Resistance as Compared to a Control.

Further study details as provided by Åsa Håkansson, Lund University:

Primary Outcome Measures:
  • The long term effect of a bilberry-based probiotic beverage on postprandial levels of serum insulin [ Time Frame: Incremental area under the curve for serum insulin from 0 min up to 120 min following the ingestion of the study product ]
    The incremental area under the curve (AUC) will be measured for the levels of postprandial serum insuling from 0 min to 120 min following ingestion of the product (included intermediate measuring time points are 30, 60 and 90 min)


Estimated Enrollment: 32
Actual Study Start Date: May 2, 2017
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Billberry
A bilberry-based probiotic beverage
Other: Bilberry
A bilberry based probiotic beverage
Active Comparator: Control
A control beverage without bilberries or probiotics
Other: beverage without bilberries or probiotics
A control beverage without bilberries or probiotics

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Healthy adults with a BMI between 20-30

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03185676

Contacts
Contact: Yvonne Granfeldt, Prof +46-70 569 33 75 yvonne.granfeldt@food.lth.se

Locations
Sweden
Klinisk Prövningsenhet, Kliniska Studier Sverige - Forum Söder Recruiting
Lund, Sweden
Contact: Yvonne Granfeldt, Prof         
Sponsors and Collaborators
Lund University
  More Information

Responsible Party: Åsa Håkansson, Associate Senior Lecturer, Lund University
ClinicalTrials.gov Identifier: NCT03185676     History of Changes
Other Study ID Numbers: InVeg (2)
Study First Received: June 12, 2017
Last Updated: June 12, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on August 18, 2017